Glioblastoma Clinical Trial
Official title:
A Randomized Phase II Trial of Aspirin for Primary Prophylaxis of Venous Thromboembolism in Glioblastoma
Primary objective:
To determine whether aspirin (ASA) can lower the incidence of Venous Thromboembolism(VTE) in
patients with Glioblastoma (GBM).
Secondary objectives:
To determine clinical and laboratory factors which are associated with increased risk of VTE
If it is determined that ASA reduces the incidence of VTE in patients with GBM, then to
determine the clinical and laboratory factors which are associated with an increased benefit
from the drug.
Study Drug:
Aspirin is designed to make blood less "sticky" and reduce its chances of clotting. By
making blood less sticky, it may be less likely to allow a clot to form.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned
(as in the toss of a coin) to 1 of 2 study groups. If you are assigned to Group 1, you will
take aspirin. If you are in Group 2, you will take a placebo. A placebo is a substance that
looks like the study drug but has no active ingredients. You will have an equal chance of
being placed in either group. Neither you nor your study doctor will know what group you are
in. In case of an emergency, the study staff will be able to find out which group you are
in.
Study Drug Administration:
If you are assigned to Group 1, you will take 1 aspirin tablet, once a day, by mouth.
Aspirin should be taken with food and may be taken at any time during the day.
If you are assigned to Group 2, you will take 1 placebo tablet once a day, by mouth. The
placebo should be taken with food and may be taken at any time during the day.
Study Visits:
While on study you will have tests and procedures performed at the same time as each routine
clinical visit and when the study doctor thinks it may be necessary. The following tests and
procedures will be performed:
- You will have a physical exam.
- You will be checked for VTE at each visit.
- Blood (2 teaspoons) will be drawn for routine tests at least once every 8 weeks. Blood
samples will not be routinely collected if you are not receiving any chemotherapy.
- Blood (about 1 teaspoon) will be drawn to see how well your blood clots about 4 months
after you begin treatment. If you show signs of VTE, this test will be done on the
first visit after the signs are shown.
Length of Study:
You may remain on-study for as long as you are benefiting. If the disease gets worse or
intolerable side effects occur, you may be taken off of the study.
End of Study Visit:
Once you are off-study, you will have an end-of-study visit. At this visit, the following
tests and procedures will be performed:
- Your complete medical history will be recorded.
- You will have a physical exam.
- You will have performance status evaluation.
- You will be asked about any medications you may be taking.
- You will be checked for VTE.
- Blood (about 1 teaspoon) will be drawn to see how well your blood clots.
- If you have symptoms of VTE, you will have a Doppler ultrasound test of your legs.
Follow-up:
The study staff will call you or a member of your family every 3 months, after your last
clinic visit, to follow your health status.
This is an investigational study. Aspirin is approved by the FDA and commercially available.
Its use in lowering the risk of VTE is investigational. Aspirin, and the study-related
tests/procedures will be provided free of charge to you while on this study. Up to 224
patients will take part in this study. All will be enrolled at M. D. Anderson.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05664243 -
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
| Recruiting |
NCT05635734 -
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03679754 -
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
|
Phase 1 | |
| Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
| Terminated |
NCT03927222 -
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
|
Phase 2 | |
| Recruiting |
NCT03897491 -
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03587038 -
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
| Recruiting |
NCT04391062 -
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03661723 -
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT02655601 -
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
|
Phase 2 | |
| Completed |
NCT02206230 -
Trial of Hypofractionated Radiation Therapy for Glioblastoma
|
Phase 2 | |
| Completed |
NCT03493932 -
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
|
Phase 1 | |
| Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Completed |
NCT03018288 -
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
|
Phase 2 | |
| Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
| Not yet recruiting |
NCT04552977 -
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Terminated |
NCT02905643 -
Discerning Pseudoprogression vs True Tumor Growth in GBMs
|